Here are Dr. Bae's expectations for the future of spine innovation and devices.
Question: Where do you see spine implant innovation heading?
Dr. Hyun Bae: We are going to see very little innovation because the pathway is very difficult. It's arduous to get a novel device through the FDA. I've seen many devices go through the FDA process that never got approval. Companies are getting very cautious about spending the amount of money that is takes to complete the trial with the risk of eventual denial.
A recent example is [Spinal Kinetics] M6, a great cervical disc used in Europe for a long time. Recently, they've withheld their trial in the U.S., thinking it may be too costly and risky. I think that in the U.S., implant-related innovation that requires an [Investigational Device Exemption] is going to be pretty rare.
Q: What type of innovation do you expect to become more prevalent?
HB: The clinical trials we are going to see for new devices and procedures will not target minimally invasive surgery but minimally invasive procedures. They will be targeting early intervention in the spinal disease cascade for interventional spine specialist and less so for spinal surgeons. Before, most of the trials were for spinal surgeons. The new clinical trials will be before both.
There is a tremendous amount of interest in clinical trials looking at degenerative disc disease and treatment of low back pain. Recent device trials were centered on disc replacement but now treatments are centered on regenerative therapies which can be performed at surgery centers, such as injecting discs with fibrin glue or stem cells and early cartilage cell growth factors. All of these clinical trials that involve the injection of discs can be done by both surgeons and interventionalists.
Q: Why will these regenerative techniques gain traction?
HB: There is a huge demand from patients that don't want surgery. I also think as the procedural morbidity cost is decreased. Patients' ultimate expectations are decreased as well. Meaning that patients will be extremely satisfied even if the treatment helps partially or only for a limited period of time.
Patients want a cure. They have been stuck in the paradigm where the cure was surgery, even though good results are sometimes difficult to guarantee. Other solutions on the pain management side are not that great either. Patients are really stuck and looking for a better alternative. The industry will follow what the consumer demands. A great interest exists in non-surgical alternatives to treating back pain. Can we regenerate discs or try to maintain them if we can intervene earlier? Also will that lead to pain relief? These questions still have to be answered but the demand and need is great.
Q: Will limited spine treatment reimbursements continue to plague the industry?
HB: There is no question that reimbursements will continue to be a problem. All clinical trials are going to have to show efficacy to get reimbursement. However these treatments have the advantage of being less costly than spinal surgery. That also has to be balanced with the fact that since the procedure is relatively easy that overuse and abuse is going to be an issue. Also a population of patients exists that will pay cash for novel procedures that are alternatives to surgery especially if you can demonstrate some efficacy. Currently there is a thriving industry on delivering stem cell therapy on a cash basis with little or no demonstration of true efficacy.
Q: Should we expect to see robotic surgeries become more common?
HB: I think truly robotic spine surgery is not going to happen. Certainly centers may use some type of mechanized aid for surgery or image guidance. But as far as a true robot, it's not going to become a must-have for spine center soon. We are nowhere close to the innovation that the da Vinci surgical system provides for urology. The technology may get there at some point, but I don't see it in the near future.
Q: How will the economy impact innovation?
HB: We are going to see consolidation between implant companies. Most spine companies will go to a direct model to pay sales reps and keep profits. Maintaining high implant costs will be difficult as hospitals are hiring more surgeons. This in effect allows hospitals to dictate pricing and implant usage. The decreased margin and the Obama device tax will hurt the bottom line and mean less innovation, less educational grants and probably less company sponsored meetings. On the sales side, this means that salaries will be lower and possibly capped. It probably means that the quality of the sales representative and service will suffer.
Q: Do you except to see an increase in stem cell usage?
HB: I think we will start seeing some stem cell technology in the operating room. Bone marrow aspirate filtration or centrifugation is already being done. With the scrutiny on BMP currently, viable alternatives are in great demand. I think stem cell technology is an attractive idea. However, the greatest barrier will again be the FDA.
More Articles on Spine:
How Large Scale Patient Education Efforts Improve Orthopedic Practices: Q&A With Steven Siwek of Medical Marketing Solutions
Tri-City Medical Center Purchases Second Renaissance Spine System
21 Spine Devices Receive FDA 510(k) Clearance in December
The Future of Spine Innovation: Q&A With Dr. Hyun Bae of Cedars-Sinai Medical Center FeaturedWritten by Heather Linder | Friday, 18 January 2013 15:32
Hyun Bae, MD, is the Director of Education at Cedars-Sinai Medical Center and the Medical Director of the Spine Institute in Santa Monica. He has researched stem cell repair for degenerative disc disease and the use of growth factors to treat spinal cord injuries. He was among the first to use growth factor tissue engineering for intervertebral discs and chaired the "Spine Across the Sea" meeting in 2012 for the North American Spine Society.Last modified on Friday, 18 January 2013 16:08
© Copyright ASC COMMUNICATIONS 2015. Interested in LINKING to or REPRINTING this content? View our policies here.
Most Read - Spine
- Spine surgery in a value-based world: Dr. Jed Vanichkachorn on spine bundled payments
- Hospital employment vs. independent practice: 5 spine surgeons weigh in
- The endless possibilities in spine biologics, artificial disc & outpatient procedures
- 5 things to know about Medicare charges for cervical spine surgery
- Dr. Todd Gravori praises stem cells for back pain relief
Top 40 Articles from the Past 6 Months
- 12 statistics on neurosurgeon salary in 2015
- North American Spine brings in two new procedures — 5 things to know
- Drs. Larry Lenke, Daniel Riew, Ronald Lehman leaving St. Louis for NYC — 5 things to know
- DePuy Synthes, Stryker, Zimmer, Medtronic lead global orthopedics now — 8 key notes on where they're headed
- Bundled spine surgery for Walmart, Lowe's employees — 6 things to know
- Medtronic is headed for strong 2015 — 8 reasons why
- 5 key trends in 3D printing medical device market
- 25 Spine Device Awards | 2015
- 20 Spine Surgeon Leadership Awards | 2015
- Neurosurgeon named in counterfeit spinal implant lawsuit — 5 things to know
- 10 spine, orthopedic surgeon tech entrepreneurs to know
- 15 things to know about Zimmer Biomet
- A differentiated approach in lateral spine surgery: Oblique lateral interbody fusion (OLIF at L2-L5)
- Top 10 specialties with highest pay — Orthopedists lead the pack
- Zimmer voluntarily recalls knee device
- Safeguards to Prevent Neurologic Complications after Epidural Steroid Injections: Analysis of Evidence and Lack of Applicability of Controversial Policies
- 6 spine physicians ranked #1 on Google
- Northwestern's Feinberg School of Medicine neurological surgery chief Dr. Andrew Parsa dies
- Are 'macho' orthopedic surgeons a hazard to patients? 5 things to know
- Dr. Aria Sabit pleads guilty to unnecessary spine surgery, faces 11+ years in prison — 5 things to know
- Is the Zimmer-Biomet closed merger finally around the corner? 5 things to know
- Dr. Neal ElAttrache to perform Manny Pacquiao's shoulder surgery: 5 things to know
- Spinal fusion vs. disc replacement: Which costs more? 5 key notes
- Medtronic pays 8 physicians $1M+: 5 key notes
- Another spine surgeon named in "fake implants" lawsuit — This time in Maryland: 5 key notes
- Building an empire: How Dr. Douglas Won created a physician-led health system
- Zimmer Q1 sales drop 2.3%, Biomet merger still not final — 10 things to know
- How The CORE Institute grew 40% last quarter — IT leads the way
- Dr. Sanjay Khurana helps rescue Harrison Ford from crashed air plane
- Is Smith & Nephew's cost-conscious strategy working? 5 key notes
- 55 statistics and issues for neurosurgeons and orthopedic spine surgeons — compensation, global device market and more
- UPMC's Dr. Tanya Hagen dies at age 45
- Hospitals face 4 lawsuits in connection with unnecessary spine surgeries case — 6 things to know
- How high-energy spine surgeons start their day — 5 things to know
- Johnson & Johnson (J&J) sells Cordis line for $1.9B: What it could mean for DePuy Synthes
- Spinal deformity surgery — On the cutting edge with Drs. Isador Lieberman, Suken Shah
- Dr. Ziya Gokaslan to leave Johns Hopkins for Rhode Island Hospital
- Cervical disc replacement Mobi-C vs. spinal fusion: Are there advantages to one? 6 key notes
- Medtronic facing product liability lawsuit over Infuse once more: 9 things to know
- Hospital for Special Surgery names Dr. Frank Schwab spine service chief — 5 things to know